Literature DB >> 10542266

Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells.

S Altiok1, D Batt, N Altiok, A Papautsky, J Downward, T M Roberts, H Avraham.   

Abstract

The breast cancer susceptibility gene BRCA1 encodes a nuclear phosphoprotein that acts as a tumor suppressor. Phosphorylation of BRCA1 has been implicated in altering its function, however, the pathway(s) that leads to the phosphorylation of BRCA1 has not been described. Here, a signaling pathway by which heregulin induces cell cycle-independent phosphorylation of BRCA1 was delineated. We showed that heregulin stimulation induced the phosphorylation of BRCA1 and concomitant activation of the serine/threonine kinase AKT in T47D human breast cancer cells. Heregulin-induced phosphorylation of BRCA1 was abrogated by phosphatidylinositol 3-kinase (PI3K) inhibitors and by a dominant-negative AKT. In the absence of heregulin, the ectopic expression of the constitutively active p110 subunit of PI3K was sufficient to induce BRCA1 phosphorylation. Furthermore, the purified glutathione S-transferase/AKT kinase phosphorylated BRCA1 in vitro. We have also shown that the phosphorylation of BRCA1 by AKT occurs on the residue Thr-509, which is located in the nuclear localization signal. These results reveal a novel signaling pathway that links extracellular signals to the phosphorylation of BRCA1 in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10542266     DOI: 10.1074/jbc.274.45.32274

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage.

Authors:  Eugene S Kandel; Jennifer Skeen; Nathan Majewski; Antonio Di Cristofano; Pier Paolo Pandolfi; Claudine S Feliciano; Andrei Gartel; Nissim Hay
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

Review 2.  Nuclear and mitochondrial signalling Akts in cardiomyocytes.

Authors:  Shigeki Miyamoto; Marta Rubio; Mark A Sussman
Journal:  Cardiovasc Res       Date:  2009-03-11       Impact factor: 10.787

3.  Bone marrow-derived mesenchymal stem cells up-regulate acetylcholine receptor delta subunit through NRG/ErbB3-mediated mitogen-activated protein kinase pathway.

Authors:  Li Chen; Junjian Jiang; Jianguang Xu; Yudong Gu; Lei Xu
Journal:  Clin Transl Sci       Date:  2012-02-23       Impact factor: 4.689

4.  Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.

Authors:  Rebecca S Muraoka-Cook; Laura S Caskey; Melissa A Sandahl; Debra M Hunter; Carty Husted; Karen E Strunk; Carolyn I Sartor; William A Rearick; Wesley McCall; Magdalene K Sgagias; Kenneth H Cowan; H Shelton Earp
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

5.  AKT regulates BRCA1 stability in response to hormone signaling.

Authors:  Andrew C Nelson; Traci R Lyons; Christian D Young; Kirk C Hansen; Steven M Anderson; Jeffrey T Holt
Journal:  Mol Cell Endocrinol       Date:  2010-01-18       Impact factor: 4.102

Review 6.  The Role of PI3K/Akt and ERK in Neurodegenerative Disorders.

Authors:  Sachchida Nand Rai; Hagera Dilnashin; Hareram Birla; Saumitra Sen Singh; Walia Zahra; Aaina Singh Rathore; Brijesh Kumar Singh; Surya Pratap Singh
Journal:  Neurotox Res       Date:  2019-02-01       Impact factor: 3.911

7.  Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function.

Authors:  Irene Guendel; Lawrence Carpio; Caitlin Pedati; Arnold Schwartz; Christine Teal; Fatah Kashanchi; Kylene Kehn-Hall
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

Review 8.  AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma.

Authors:  K J Schmitz; H Lang; J Wohlschlaeger; G C Sotiropoulos; H Reis; K W Schmid; H A Baba
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

9.  Akt promotes tumorigenesis in part through modulating genomic instability via phosphorylating XLF.

Authors:  Wenjian Gan; Pengda Liu; Wenyi Wei
Journal:  Nucleus       Date:  2015-07-30       Impact factor: 4.197

10.  The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins.

Authors:  B L Smith; D Chin; W Maltzman; K Crosby; G N Hortobagyi; S S Bacus
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.